安派科(AnPac Bio)在美获得重要新型微型医疗设备专利 (英文)

自媒体 自媒体

[本文来自:www.777y.com]

AnPac Bio Granted Important Novel Micro Medical Device Patent in the United States

  [好文分享:www.777y.com]

NEWS PROVIDED BY AnPac Bio-Medical Science Co., Ltd. 


SAN JOSE, Calif., March 24, 2020 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today the allowance by  the United States Patent and Trademark Office on March 5, 2020, of a US patent application claiming an integrated and decomposable micro apparatus that can be used for site-specific delivery of a drug, a medical kit, a micro disease detection system, or even an auto-navigation system for in vivo applications.


Cancer Differentiation Analysis Technology


"As a leader in using biophysical properties to scan and detect changes in blood and other liquid samples, we wanted to make sure that our technology and patents also include our devices to have the option of being in vivo so that we can constantly test and detect changes in the in the human body," said Dr. Chris Yu, CEO and Chairman of AnPac Bio. "Due to our fundamental pending and issued patents in the US and many other jurisdictions covering the entire spectrum of disease detection, as well as micro surgical operations and drug release responses, intellectual properties of biophysical measurements with multi-functional micro- medical devices will have significant value in the future."


About AnPac Bio


AnPac Bio is a biotechnology company focused on early cancer screening and detection with two certified clinical laboratories in China and one CLIA registered clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests. In a recent market research report by Frost & Sullivan, AnPac Bio ranked second worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection, based on approximately 35,000 clinical samples as at June 30, 2019. AnPac Bio's CDA technology has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity.


For more information, please visit: https://www.Anpacbio.com.


For investor and media inquiries, please contact:


Company:
Phil Case, Marketing and Investor Relations
Email: phil_case@AnPacbio.com

Investor Relations:
Ascent Investor Relations LLC
Tina Xiao, President
Email: tina.xiao@ascent-ir.com   


Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. The Company has attempted to identify forward-looking statements by terminologies including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "target," "aim," "predict," "outlook," "seek," "goal" "objective," "assume," "contemplate," "continue," "positioned," "forecast," "likely," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, the implementation of our business model and growth strategies; trends and competition in the cancer screening and detection market; our expectations regarding demand for and market acceptance of our cancer screening and detection tests and our ability to expand our customer base; our ability to obtain and maintain intellectual property protections for our CDA technology and our continued research and development to keep pace with technology developments; our ability to obtain and maintain regulatory approvals from the NMPA, the FDA and the relevant U.S. states and have our laboratories certified or accredited by authorities including the CLIA; our future business development, financial condition and results of operations and our ability to obtain financing cost-effectively; potential changes of government regulations; general economic and business conditions in China and elsewhere; our ability to hire and maintain key personnel; and our relationship with our major business partners and customers. Additionally, all forward-looking statements are subject to the "Risk Factors" detailed from time to time in the Company's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.


转自prnewswire.com 起原 SOURCE AnPac Bio-Medical Science Co., Ltd.

本文由「华尔街俱乐部」介绍,敬请关注公家号: wallstreetclub

声明:本文仅代表作者个人概念,不构成投资定见,并不代表本平台立场。文中的论说和概念,敬请读者留意判断。

版权声明:「华尔街俱乐部」除发布原创市场投研申报外,亦致力于优良财经文章的交流分享。部门文章、图片和资料来自收集,版权归原创。推送时未能实时与原作者取得关系。若涉及版权问题,敬请原作者添加WSCHELP微信关系删除。感激授权使用!

免责声明:「华尔街俱乐部」竭力供给准确而靠得住的资讯,惟不保证绝对无误,资讯如有讹夺而令旁边承受损失(不论是否与侵权行为、订立契约或其他方面有关),本号概不负责。同时,「华尔街俱乐部」所供给之投资理会花样与建议,只可作为参考之用,并不构成要约、招揽、邀请、诱使、任何不论种类或形式之申述或订立任何建议及介绍,读者务请运用个人自力思虑能力自行作出投资决意,如因相关建议招致损失,概与「华尔街俱乐部」、编纂及记者无关。

华尔街俱乐部凝聚华尔街投行的高端资源,为中国民营企业“走出去”供给全方位的咨询人处事,包括企业赴美上市、计策投资、并购、私募路演和投资者关系等。在投资理念和手艺方面供给华尔街投行专家实战培训,为您进入华尔街铺设成功之路。




自媒体微信号:777y扫描二维码关注公众号
爱八卦,爱爆料。
小编推荐
  1. NO.1 盘点只有老司机才听过的英雄台词,孙尚香和芈

    上次猫叔收集了一些霸气的英雄台词 受到了老铁们的喜欢 虽然你们没有直说 但是从你们积极的后台留言当中 猫叔 就可以看出来 以后有什么你们想

  2. NO.2 啪啪时女票超能夹紧是什么感觉?

    从前有个人,人称3X哥。X哥爱污漫,一画不吃饭,天天开火车,呜呜呜呜呜,呆萌爱搞笑,逗比又好色。既爱啪啪啪,也爱么么哒,键盘遥控器,榴

  3. NO.3 香甜软糯中透着阵阵肉香,可把人馋坏了!

    香甜软糯的板栗既是厚味的小零嘴,同时也是入菜的好搭配。今天分享一道应季的厚味佳肴,把板栗、南瓜等食材和排骨一路烧制,给浓烈的肉香增

  4. NO.4 “你忍着点,拨出来时会有点疼。”

    第1章 接受不了 “别,别在我爸面前做!不要!” 宋斯曼无数在顾少霆的身下承欢,卫生间,办公室,楼道间,野外,每次她都浪着声求顾少霆给她

  5. NO.5 中国知网免费入口学生登录(2019知网账号密码分享)

    2017年知网的收入高达9.7亿,毛利率高达61%,之前的毛利率最高可达到72%。知网查重是大学生毕业前的梦魇,不仅是担心过不了查重,还因为知网查重

  6. NO.6 2019剑灵什么职业厉害(剑灵9大职业排名)

    都说现在剑灵里有个狗职业叫召唤,副本有用输出强势;而一年前的狗职业剑士现在地位不如以前,被戏称为剑大海,输出垫底。 由于剑灵目前还没有

  7. NO.7 《勇者斗恶龙 创世小玩家2》攻略:建造技巧与注意事项。

    想要精巧地体验DQB2,光把游戏通关,找到图纸是远远不足的,游戏中的建筑机制和弄法才是本作的真正核心。不过这里只给各位介绍一些关键影响到

  8. NO.8 微信月活跃用户数量有多少(2019微信年度数据报告)

    以下56个app你手机上安装了什么呢?评论区见! 微信,qq,淘宝网,爱奇艺,支付宝,微博,搜狗,腾讯视频,前八名,微信目前11亿的月活跃用户

Copyright2018.七云自媒体资讯站,让大家及时掌握各行各业第一手资讯新闻!